Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

61.56
Delayed Data
As of Jul 02
 +0.61 / +1.00%
Today’s Change
47.36
Today|||52-Week Range
68.75
+7.04%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Generic
MARKET CAP
$59.1B

Company Description

Teva Pharmaceutical Industries Ltd. engages in the provision of pharmaceutical services. It operates through the following business divisions: Generic, Specialty Medicine, and Over-the-Counter (OTC). The Generic division involves the manufacture and sale of generic products such as tablets, capsules, ointments, creams, liquids, injectables, and inhalants. The Specialty Medicine division provides products for central nervous system (CNS), respiratory system, women's health, oncology, and others. The OTC division offers medicines in categories such as cough and cold, allergy, digestive wellness, vitamins, minerals and supplements, analgesics, and skin medications. Its products are manufactured under the Copaxone, Provigil, Azilect, Nuvigil, ProAir, Qvar, Treanda, Lonquex, Revascor, Milprosa, LeCette, Quartette, NexoBrid, and StemEx brand names. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.

Contact Information

Teva Pharmaceutical Industries Ltd.
5 Basel Street
Petach Tikva Tel Aviv 49131
P:(723) 926-7267
Investor Relations:
(215) 591-8912

Employees

Shareholders

Mutual fund holders29.23%
Other institutional26.12%
Individual stakeholders--

Top Executives

Erez VigodmanPresident, Chief Executive Officer & Director
Carlo de NotaristefaniPresident & CEO-Global Operations
Eyal DeshehChief Financial Officer & Group Executive VP
Michael R. HaydenPresident-Global Research & Development
Eric DrapéExecutive Vice President & Head-Quality

To view my watchlist

Not a member yet?

Sign up now for a free account